A programme to create short-course chemotherapy for pulmonary Mycobacterium avium disease based on pharmacokinetics/pharmacodynamics and mathematical forecasting
Open Access
- 1 September 2017
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 72 (suppl_2) , i54-i60
Abstract
Pulmonary Mycobacterium avium complex (MAC) prevalence is on the rise worldwide. The average therapy duration is 1.5 years, which is associated with poor cure rates. Our objective was to develop a programme to design a combination therapy regimen for pulmonary MAC to be administered for 6 months or less with efficacy in > 90% of patients. We performed a literature search for the following MeSH headings ‘Mycobacterium avium’ AND ‘pharmacokinetics/pharmacodynamics’ in PubMed up to 2016. The findings were then used to identify steps in the programme to design new regimens with faster microbial kill rates than the current standard regimen. First, we designed a strategy for rapid in vitro screening of all antibiotic classes for repurposing against pulmonary MAC. Secondly, we identified and compared maximal microbial kill rates (Emax), and optimal exposures of eight different antibiotics. These studies had all been performed in the hollow-fibre system model of pulmonary MAC (HFS-MAC). Thirdly, all drugs with a high Emax at clinically achievable optimal exposures will be chosen, and exposures associated with synergy or additivity for two/three drugs identified based on Bliss independence. Fourthly, the time–kill slopes and resistance suppression of the chosen combinations will be compared with those of standard combination therapy in the HFS-MAC. Finally, we will identify the clinical doses best able to achieve synergistic or additive combination exposures by taking into account pharmacokinetic variability. Our stepwise pharmacokinetics/pharmacodynamics approach provides a scientific rationale and a strategy for achieving short-course chemotherapy for pulmonary MAC disease within a few years.Keywords
This publication has 64 references indexed in Scilit:
- Pulmonary Mycobacterium avium-intracellulare is the main driver of the rise in non-tuberculous mycobacteria incidence in England, Wales and Northern Ireland, 2007–2012BMC Infectious Diseases, 2016
- Population-based Incidence of Pulmonary Nontuberculous Mycobacterial Disease in Oregon 2007 to 2012Annals of the American Thoracic Society, 2015
- Bronchiectasis and Nontuberculous Mycobacterial DiseaseClinics in Chest Medicine, 2012
- Distribution of mycobacterial antigen based on differences of histological characteristics in pulmonary Mycobacterium avium infectious diseases—Consideration of the extent of surgical resection from the pathological standpointPathology - Research and Practice, 2012
- Changing Epidemiology of Pulmonary Nontuberculous Mycobacteria InfectionsEmerging Infectious Diseases, 2010
- Pulmonary Nontuberculous Mycobacterial Disease Prevalence and Clinical Features: An Emerging Public Health DiseaseAmerican Journal of Respiratory and Critical Care Medicine, 2010
- Mycobacterium avium-intracellulare Pulmonary Infection in HIV-Negative Patients Without Preexisting Lung DiseaseChest, 1999
- Epidemiology of infection by nontuberculous mycobacteriaClinical Microbiology Reviews, 1996
- Mycobacterium avium Complex Pulmonary Disease Presenting as an Isolated Lingular or Middle Lobe PatternChest, 1992
- Infection withMycobacterium aviumComplex in Patients without Predisposing ConditionsNew England Journal of Medicine, 1989